DY
Therapeutic Areas
Omnix Medical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OMN51 | Multidrug‑resistant Gram‑negative bacterial infections (e.g., Pseudomonas aeruginosa) | Preclinical |
Leadership Team at Omnix Medical
DM
Dr. Moshik Cohen‑Kutner
Co‑Founder & CEO
DN
Dr. Niv Bachnoff
Co‑Founder & CSO
DA
Dr. Antonius Schuh
Chairman of the Board
TG
Tomer Goldberg
Vice President, Managing Director, Harel Technology Investments
ED
Eyal Dior
Founder & Managing Partner, Tal Ventures